anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adenosine triphosphate (ATP) is an established vasodilator that is released from red blood cells during a variety of stimuli including exercise and exposure to hypoxic environments. Many studies have shown that infusion of ATP can lead to vasodilation similar to that which is achieved during exercise, and that plasma ATP concentrations increase in a graded fashion during graded exercise. Further, older adults have lower levels of blood flow during exercise and hypoxia compared to their younger counterparts, and the reduced blood flow is coupled with impaired release of ATP from red blood cells during these stimuli. Thus, ATP is believed to be an important vasodilator. However, the role of ATP in the regulation of blood flow is not fully understood due to the lack of an effective ATP receptor (P2Y2) antagonist. Development of an effective P2Y2 antagonist will allow researchers to determine the role of ATP in vasodilation to stimuli such as exercise by comparing blood flow during exercise with and without the blocker. Preliminary data from our laboratory suggests that Vitamin B6 (pyridoxine hydrochloride) or its metabolite Pyridoxal-5-Phosphate (PLP) may be an effective blocker of ATP-mediated vasodilation. As a result, the purpose of this study is to determine whether Vitamin B6 or PLP can inhibit vasodilation in response to intra-arterial infusions of ATP. This study also aims to determine the specificity of Vitamin B6 or PLP by measuring its effect on vasodilation in response to infusion of several other vasodilators.

Participants will be asked to complete one screening visit and one study visit. Once study eligibility has been determined, participants will report to the Human Performance Clinical Research Laboratory at Colorado State University following an overnight fast. A physician will then place a catheter in the brachial artery of the non-dominant arm, and participants will be randomized into one of three study arms to determine which drugs will be infused into the artery. Each arm includes ATP and two other vasodilators. The study will begin by measuring vasodilation in response to four standard doses of each vasodilator. Vasodilation in response to the vasodilators will then be assessed again following infusion of Vitamin B6 or PLP. Reduced vasodilation to any of the drugs during the second trial will suggest that Vitamin B6 or PLP is an antagonist to the channel through which the drug signals. Each study visit will last approximately 4-5 hours.
The utility model relates to a pearl powder preparation equipment, in particular to a nanometer-grade pearl powder preparation device, comprising a water tank. A water flushing gap is arranged at one side of the water tank, while the wall body for the opposite side of it is inclined to be a slope. A collecting gap with filtrating screen is provided at the middle of the slope. A raw material stirring machine is provided under the bottom of the water tank between the water flushing gap and the slope. The stirring cavity of the stirring machine is connected with the water tank in a sealing way and the cavity orifice is communicated with the water tank. The utility model can make sure the collected pearl powder can achieve the nanometer grade so as to greatly reduce the heavy metal content of it , which is simple in structure and saves time and energy, and at the same time can be applied for industrial production.
PURPOSE:To provide a composition for oral cavity application exhibiting high antibacterial activity on oral bacteria, having excellent usability and effective for the prevention and treatment of various diseases in the oral cavity (e.g. dental caries, foul breath and periodontosis). CONSTITUTION:The composition for oral cavity application contains (A) 0.001-1% (especially 0.01-0.5%) grape extract produced by extracting grape with a solvent, removing insoluble solid residue by a solid-liquid separation means and removing the solvent from the solvent-extract solution by vacuum distillation, etc., and (B) 0.005-1% (especially 0.01-0.5%) 1,8-cineole. The astringent taste of grape can be masked by the compounding of 1,8-cineole without lowering the antibacterial activity originated from the solvent extract of grape. Accordingly, the obtained composition for oral cavity application keeps high antibacterial activity and has remarkably improved usability. The composition is used in the form of a refreshing liquid for mouth such as dentifrice and mouth wash, a refreshing solid for mouth such as troche, a chewing gum, a pasta for oral cavity, etc.
A randomized controlled trial with parallel arms (HIFCT-P and HIFCT-C) based on a non-inferiority hypothesis comparing two proportions. Each participant will carry out 30 sessions, three times a week, in a virtual environment. General, concentrated, and block circuits will be used, with the same exercises, but with different load distribution and different order between them. Both HIFCT-P and HIFCT-S will carry out six initial adaptation sessions through a general circuit composed of 12 exercises. Different muscle groups will be alternated. The exercises will be performed at speeds between 35 and 55 beats per minute (bpm), to ensure intensities between 50% - 60% in sessions 1 to 3, and between 70% - 80% in sessions 4 to 6. The Modified Borg Rating of Perceived Exertion Scale (RPE) will be used to control intensities. From session seven to session 30, HIFCT-P and HIFCT-S will perform the same exercises but with a different load distribution.
Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone PO BID on days 1-5. Patients also receive asparaginase IM or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are CD20 positive and Philadelphia chromosome negative also receive rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
in the same pha,,c or in a p solution.8. A dermatological means, in particular for treating wounds, ulcers (diabetes) nd/orother skin diseases, comprising an electrochemically activated solution o any of claims 1 to 5. 9. A disinfectant comprising an electrochemically activated soluti1 to 5, 10. Use of an electrochemically activated solution of any pharmaceutical composition. of any of claims 1 to 5 in a Electrochemically acti ted water-based solution and use of the solution An electrochemically -' ivated water-based solution, obtained by electrolysis of briny water in an electrol is module (2) comprising a plurality of electrolysis cells (40), shall exhibit a particu rly high bactericidal or antibacterial effect and, at the same time, a particularly ha storage stability, i.e. in particular even after a relatively long storage of, for exam" -,more than two years. According to the invention, such a solution is obtain; • by electrolysis of briny water in an electrolysis module (2) comprising aplu ity of electrolysis cells (40), each electrolysis cell (40) comprising a first electrodeace assigned to a first electric polarity and a second electrode space separatedtherefrom-byna-diaphragm-(46)-and-assigned-to-a-secon-d-ele-ctric-polatitywherein-the electrolyte is serially fed to the first electrode spaces of the electrolysis cells (40) in the Abstract Electrochemically activated water-based solution and use of the solutionAn electrochemically activated water-based solution, obtained by dlectrolysis of briny water in an electrolysis module (2) comprising a plurality of electrolysis cells (40), shall exhibit a particularly high bactericidal or antibacterial effect and, at the same time, a particularly high storage stability, i.e. in particular even after a relatively long storage of, for example, more than two years According to the invention, such a solution is obtained by electrolysis of briny water in an electrolysis module (2) comprising a plurality of electrolysis cells (40), each electrolysis cell (40) comprising a first electrode space assigned to a first electric polarity and a second electrode space separated therefrom by a diaphragm (46) and assigned to a second electric polarity, wherein the electrolyte is serially fed to the first electrode spaces of the electrolysis cells (40) in the manner of a series connection.
BACKGROUND: Research has demonstrated that sarcopenia and visceral obesity are significant risk factors for chronic disease in middle-aged and older adults. However, the relationship between sarcopenia, the cardiac metabolic index (CMI), a novel measure of visceral obesity, and cardiometabolic multimorbidity (CMM) remains unclear. In this study, data from the China Longitudinal Study of Health and Retirement (CHARLS) were analyzed to investigate the association between sarcopenia and CMI with CMM in the middle-aged and older adult population.
METHODS: The study included 4,959 participants aged 45 and over. Sarcopenia was defined using the criteria of the Asian Sarcopenia Working Group 2019. CMM is defined as having two or more of the following conditions: physician-diagnosed heart disease, diabetes, stroke, and/or hypertension. CMI was calculated using the formula: CMI = (TG/HDL-C) × WHtR. To explore the association between CMI and sarcopenia and CMM, cox proportional risk regression models were used.
RESULTS: The median age of all participants was 57 years, with 47.1% being male. Over the 8-year follow-up, 1,362 individuals developed CMM. The incidence of CMM was 8.7/1,000 person-years in the group without sarcopenia or high CMI, 17.37/1,000 person-years in those with high CMI, 14.22/1,000 person-years in the sarcopenia group, and 22.34/1,000 person-years in the group with both conditions. After adjusting for covariates, the group with both sarcopenia and high CMI had a significantly increased risk of CMM (HR 2.48, 95% CI 1.12-5.51) and heart disease (HR 2.04, 95% CI 1.05-3.98). Among those over 65 years, sarcopenia was discovered to be associated with an increased risk of CMM [HR (95% CI: 4.83 (1.22, 19.06)]. The risk of CMM was further increased to 7.31-fold (95% CI:1.72, 31.15) when combined with high CMI.
CONCLUSIONS: The combination of sarcopenia and high CMI is associated with an increased risk of developing CMM. Early identification and intervention of sarcopenia and CMI not only enable the development of targeted therapeutic strategies but also provide potential opportunities to reduce the morbidity and mortality of CMM.
This invention provides a method for establishing hetero-hybrid tumor engineering cell sequence for producing human monoclonal antibody for anti-hepatitis B virus. The anti-HBs positive human splenic lymph cell (SL) is fused with mouse plasmacytoma sequence P3-X63/Ag8-653 cell. Limiting dilution method is used for cloning the positive antibody poro-hybrid-tumor cell to obtain hetero hybrid tumor engineering cell sequence which produces human monoclonal antibody for anti-hepatitis B virus, with stable and high product, rate. Said monoclonal antibody is proceeded with purification and cross-linkage with interferon to produce target prepn. of anti-hepatitis B virus human monoclonal antibody crosslinking with itnerferon, and passive immune prepn. for hepatitis B, and testing agent for hepatitis B.
FIELD: medicine, veterinary science, cosmetics. SUBSTANCE: invention describes method for preparing water-soluble forms of chitosan. Method involves preparing the chitosan homogenous solution, its isolation by treatment with alkaline agent to pH value 6.9-7.5, amorphization of chitosan as it an aqueous suspensions in cavitating or mechanical fields with shifting effect. The interaction of the prepared suspension with inorganic, organic acids or their anhydrides and isolation of the end compound from solutions in demineralized water by method of spraying or sublimating drying. Method involves using chitosan of polyfractional composition by molecular mass (from ~ 100 kDa to a monomer link glucosamine) and deacetylation degree from 68 to ≥ 95%) in the mole ratio of amino-groups of all chitosan fractions and inorganic acid = 1 : (0.08-1), amino-groups of all chitosan fractions and organic acid = 1 : (0.8-1.2), amino- groups of chitosan fractions and organic acid anhydride = 1 : (1-1.4). Invention provides ecological purity and effectiveness of method for preparing being without usage of organic solvents, expanded spectrum of biological activity owing to the usage of chitosan with polyfractional composition. EFFECT: improved preparing method. 6 ex
Facebook users in the area receive ads which include videos of health professionals encouraging them to nominate their most influential friends to help their friends get vaccinated. The difference from Treatment 2 is that the health professionals call on Facebook users to get their most influential friends to do the convincing about the vaccine. There is also a link in the ad to a website built by the study team. This website hosts videos which answer common questions about vaccination (the same videos that are directly served to Facebook users in Treatment 1).
The invention discloses compound Chinese herbal medicinal granules for preventing and curing porcine reproductive and respiratory syndrome of a pregnant sow. The granules comprise the following components, by weight, 20-30 parts of angelica roots, 20-30 parts of prepared rehmannia roots, 10-20 parts of stir-fried white peony roots, 5-10 parts of stir-fried mugwort leaves, 5-10 parts of honeysuckle flowers, 5-10 parts of bitter oranges, and 5-10 parts of motherwort herbs. The compound Chinese herbal medicinal granules are reasonable in formula, simple to prepare, and comparably uniform through step-by-step mixing. The Chinese herbal medicinal composition is green, is free of medicine residues and high in bioavailability, and is an ideal medicine substitute of antibiotics. According to a traditional theory of traditional Chinese veterinarian, six Chinese herbal medicines are preferably selected, and form pure Chinese herbal medicinal granules based on a preferable ratio. It is proved through clinical application that the granules have a special effect on curing porcine reproductive and respiratory syndrome of a sow, and the cure rate can reach 98%.
Participants with R/R DLBCL will receive 6 months of induction treatment with fixed dose of polatuzumab vedotin and rituximab along with dose escalating lenalidomide. Lenalidomide will be administered at escalating doses to identify the recommended Phase 2 dose (RP2D) for lenalidomide. Those who achieve CR and PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 6-month consolidation regimen consisting of lenalidomide and rituximab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
BACKGROUND: High blood pressure (BP) induces left atrial structural and functional remodeling that increases susceptibility to atrial arrhythmia. We hypothesized that lower systolic BP (SBP) levels are associated with a lower prevalence of premature atrial contractions (PACs) in patients with hypertension.
METHODS: This analysis included 4,697 participants (mean age 62±13.1 years, 50% women, 25.6% blacks) with hypertension from the Third National Health and Nutrition Examination Survey who did not have a prior history of cardiovascular disease (CVD). Multivariable logistic regression was used to examine the cross-sectional association between SBP and prevalence of PACs ascertained from 12-lead resting electrocardiograms. Multivariable Cox proportional hazard analysis was used to examine the association between baseline PACs and CVD mortality.
RESULTS: Approximately 1.6% (n=74) of participants had baseline PACs. Patients with SBP ≤140 mmHg had a lower prevalence of PACs than those with SBP ≥140 mmHg (1.1% vs. 1.9%, p-value=0.01). In a multivariable logistic regression model, each 10 mmHg decrease in SBP was associated with a 12% lower odds of PACs (OR (95%CI): 0.88 (0.77-0.99)). During 14 years of follow-up, 645 CVD deaths occurred. In a multivariable-adjusted Cox model, presence of PACs was associated with a 78% increased risk of CVD mortality (HR (95%CI): 1.78 (1.23-2.60)).
CONCLUSIONS: In patients with hypertension, lower SBP levels are associated with a lower prevalence of PACs, and presence of PACs is associated with a higher risk of CVD mortality risk. These findings highlight the potential role of BP lowering in the management of cardiac arrhythmias.
Behavioral: Experimental Web-based guided self-help Program This intervention will involve counselor training and student use of the developed program. Counselors will complete training and invite students to participate, and will monitor and guide students in completing the series of 8 web-based sessions based on Acceptance and Commitment Therapy.
The invention relates to external medicinal powder for treating bromhidrosis, which can be used for effectively treating the bromhidrosis. The external medicinal powder comprises the raw materials: 40-50g of hydrargrum oxydatum crudum, 10-20g of clove flos caryophylli, 5-15g of borneol and 0.02-0.06g of chlorpheniramine maleate. The external medicinal powder is prepared by the steps of pulverizing the raw materials and fully and uniformly mixing. The chlorpheniramine maleate is a market tablet: 4mg/tablet. The external medicinal powder is adhered by using a common cotton swab, coated on the fossa axillaris and used 1-2 times, the medicine effect can be sustained for above 15 days, and the external medicinal powder can be repeatedly used until peculiar smell is generated. The external medicinal powder has the advantages of simplicity in preparation, convenience for use, quickness in taking effect, long sustaining time, and remarkable social and economic benefits, and is a creation of external medicines for patients suffering from bromhidrosis.
Chronic low back pain may be associated with pathoanatomical, neurophysiological, physical, psychological and social factors. Treatments that relieve the symptoms of these patients are of great importance to improve the quality of life of these individuals. Thus, this study aims to evaluate the effects of transcranial direct current stimulation combined with Pilates based exercise on chronic low back pain. This is a randomized clinical trial that will be composed of men and women between 18 and 65 years of age, with a history of low back pain for more than 12 weeks and a minimum pain intensity equal to 3 cm on the numerical pain scale. The volunteers will be randomized into two distinct groups: stimulation + exercise group (EG - will perform a Pilates based exercise protocol combined with transcranial direct current stimulation) and sham stimulation + exercise group (SG - will perform the same exercise program combined with sham stimulation). The interventions, regardless of the group, will be carried out three times a week for four weeks. Participants will be submitted to three assessments: the first (T0) will be performed before the treatment protocols; the second (T1) will be performed after the four weeks of intervention; and the third (T2) will be a follow-up one month after the end of the treatment protocol. Pain sensation, functional performance, central sensitization, quality of life, pressure pain threshold, global impression of change, adverse events and medication use will be evaluated. For the statistical analysis, a mixed model ANOVA will be performed for the inter and intragroup comparison, with Tukey's post hoc, considering a significance level of 5%.
BACKGROUND: The incidental finding of a pericardial effusion (PE) poses a challenge in clinical care. PE is associated with malignant conditions or severe cardiac disease but may also be observed in healthy individuals. This study explored the prevalence, determinants, course, and prognostic relevance of PE in a population-based cohort.
METHODS AND RESULTS: The STAAB (Characteristics and Course of Heart Failure Stages A/B and Determinants of Progression) cohort study recruited a representative sample of the population of Würzburg, aged 30 to 79 years. Participants underwent quality-controlled transthoracic echocardiography including the dedicated evaluation of the pericardial space. Of 4965 individuals included at baseline (mean age, 55±12 years; 52% women), 134 (2.7%) exhibited an incidentally diagnosed PE (median diameter, 2.7 mm; quartiles, 2.0-4.1 mm). In multivariable logistic regression, lower body mass index and higher NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels were associated with PE at baseline, whereas inflammation, malignancy, and rheumatoid disease were not. Among the 3901 participants attending the follow-up examination after a median time of 34 (30-41) months, PE was found in 60 individuals (1.5%; n=18 new PE, n=42 persistent PE). Within the follow-up period, 37 participants died and 93 participants reported a newly diagnosed malignancy. The presence of PE did not predict all-cause death or the development of new malignancy.
CONCLUSIONS: Incidental PE was detected in about 3% of individuals, with the vast majority measuring <10 mm and completely resolving. PE was not associated with inflammation markers, death, incident heart failure, or malignancy. Our findings corroborate the view of current guidelines that a small PE in asymptomatic individuals can be considered an innocent phenomenon and does not require extensive short-term monitoring.
Patients will have angiography performed using 5Fr sheath. If PCI required, sheath will be upsized.